Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in efficacy. In the absence of head-to-head randomized control trials (RCTs), we utilized network meta-analysis (NWM) provide an indirect comparison their A systematic literature review NWM were performed using RCTs that investigated ± setting. The primary outcome was comparative overall survival (OS), while secondary outcomes progression-free (PFS), objective response rate (ORR), grade 3 higher toxicities. We identified 24 RCTs. Patients treated mAb + compared showed superior mOS, mPFS, ORR a similar This difference mOS most pronounced TPS 1–49% population. two as single agents. improved when monotherapy, whereas did not monotherapy. Head-to-head warranted future.